{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:21:26Z","timestamp":1791872486394,"version":"4.3.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T00:00:00Z","timestamp":1656028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T00:00:00Z","timestamp":1656028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"GlaxoSmithKline GmbH & Co. KG."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s41669-022-00344-4","type":"journal-article","created":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T20:12:21Z","timestamp":1656101541000},"page":"619-628","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Healthcare Resource Utilization and Cost of Patients with Multiple Myeloma in Germany: A Retrospective Claims Data Analysis"],"prefix":"10.1007","volume":"6","author":[{"given":"Zeki","family":"Kocaata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Wilke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Welte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,24]]},"reference":[{"issue":"27\u201328","key":"344_CR1","doi-asserted-by":"publisher","first-page":"470","DOI":"10.3238\/arztebl.2016.0470","volume":"113","author":"C Gerecke","year":"2016","unstructured":"Gerecke C, Fuhrmann S, Strifler S, Schmidt-Hieber M, Einsele H, Knop S. The diagnosis and treatment of multiple myeloma. Deutsches Arzteblatt Int. 2016;113(27\u201328):470\u20136. https:\/\/doi.org\/10.3238\/arztebl.2016.0470.","journal-title":"Deutsches Arzteblatt Int"},{"issue":"6","key":"344_CR2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492.","journal-title":"CA Cancer J Clin"},{"key":"344_CR3","unstructured":"Robert Koch Institut. Cancer in Germany 2015\/2016. 12th edition. Zentrum F\u00fcr Krebsregisterdaten, vol. 12, no. 1, p. 158, 2015, [Online]. https:\/\/www.krebsdaten.de\/Krebs\/EN\/Content\/Publications\/Cancer_in_Germany\/cancer_chapters_2015_2016\/cancer_germany_2015_2016.pdf?__blob=publicationFile. Accessed 4 Feb 2020."},{"issue":"SUPPL","key":"344_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12032-010-9542-z","volume":"27","author":"F Gay","year":"2010","unstructured":"Gay F, Palumbo A. Management of disease- and treatment-related complications in patients with multiple myeloma. Med Oncol. 2010;27(SUPPL):1. https:\/\/doi.org\/10.1007\/s12032-010-9542-z.","journal-title":"Med Oncol"},{"key":"344_CR5","doi-asserted-by":"publisher","unstructured":"Regional differences in the treatment approaches for relapsed multiple myeloma: an IMF study. J Clin Oncol. https:\/\/doi.org\/10.1200\/jco.2012.30.15_suppl.8095. Accessed 4 Feb 2020.","DOI":"10.1200\/jco.2012.30.15_suppl.8095"},{"issue":"5","key":"344_CR6","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2013.313","volume":"28","author":"SK Kumar","year":"2014","unstructured":"Kumar SK, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28(5):1122\u20138. https:\/\/doi.org\/10.1038\/leu.2013.313.","journal-title":"Leukemia"},{"issue":"2","key":"344_CR7","doi-asserted-by":"publisher","first-page":"230","DOI":"10.6004\/jnccn.2017.0023","volume":"15","author":"SK Kumar","year":"2017","unstructured":"Kumar SK, et al. Multiple myeloma, version 3.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2017;15(2):230\u201369. https:\/\/doi.org\/10.6004\/jnccn.2017.0023.","journal-title":"J Natl Compr Cancer Netw"},{"key":"344_CR8","doi-asserted-by":"publisher","unstructured":"Guglielmelli T, Palumbo A. Multiple myeloma: is a shift toward continuous therapy needed to move forward? Expert Rev Hematol. 2015;8(3): 253\u2013256. Expert Reviews Ltd. https:\/\/doi.org\/10.1586\/17474086.2015.1001360.","DOI":"10.1586\/17474086.2015.1001360"},{"issue":"30","key":"344_CR9","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.1200\/JCO.2014.60.2466","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, et al. Continuous therapy versus fixed duration of therapy in patients with newly diagnosed multiple myeloma. J Clin Oncol. 2015;33(30):3459\u201366. https:\/\/doi.org\/10.1200\/JCO.2014.60.2466.","journal-title":"J Clin Oncol"},{"issue":"11","key":"344_CR10","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1038\/leu.2017.111","volume":"31","author":"NJ Bahlis","year":"2017","unstructured":"Bahlis NJ, et al. Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial. Leukemia. 2017;31(11):2435\u201342. https:\/\/doi.org\/10.1038\/leu.2017.111.","journal-title":"Leukemia"},{"issue":"29","key":"344_CR11","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","volume":"35","author":"PL McCarthy","year":"2017","unstructured":"McCarthy PL, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017;35(29):3279\u201389. https:\/\/doi.org\/10.1200\/JCO.2017.72.6679.","journal-title":"J Clin Oncol"},{"issue":"10","key":"344_CR12","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa1402551","volume":"371","author":"L Benboubker","year":"2014","unstructured":"Benboubker L, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014;371(10):906\u201317. https:\/\/doi.org\/10.1056\/NEJMoa1402551.","journal-title":"N Engl J Med"},{"key":"344_CR13","doi-asserted-by":"publisher","unstructured":"D. Meade, M. Ng, S. Alford. Lenalidomide use in multiple myeloma. 2020;38(15_suppl):e14045\u2013e14045. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_SUPPL.E14045.","DOI":"10.1200\/JCO.2020.38.15_SUPPL.E14045"},{"issue":"8","key":"344_CR14","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/sj.leu.2404278","volume":"20","author":"M Cavo","year":"2006","unstructured":"Cavo M. Proteasome inhibitor bortezomib for the treatment of multiple myeloma. Leukemia. 2006;20(8):1341\u201352. https:\/\/doi.org\/10.1038\/sj.leu.2404278.","journal-title":"Leukemia"},{"issue":"12 Suppl 13","key":"344_CR15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2174\/138920106779116919","volume":"14","author":"SV Rajkumar","year":"2000","unstructured":"Rajkumar SV. Thalidomide in multiple myeloma. Oncology (Williston Park). 2000;14(12 Suppl 13):11\u20136. https:\/\/doi.org\/10.2174\/138920106779116919.","journal-title":"Oncology (Williston Park)"},{"issue":"10","key":"344_CR16","doi-asserted-by":"publisher","first-page":"e401","DOI":"10.1016\/j.clml.2018.06.018","volume":"18","author":"M Mohty","year":"2018","unstructured":"Mohty M, et al. Multiple myeloma treatment in real-world clinical practice: results of a prospective, multinational, noninterventional study. Clin Lymphoma Myeloma Leuk. 2018;18(10):e401\u201319. https:\/\/doi.org\/10.1016\/j.clml.2018.06.018.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"344_CR17","doi-asserted-by":"crossref","unstructured":"Dao Tran P, Kamalakar R, Shivaji Manthena MS, Karve S. No economic burden of multiple myeloma: results from a large employer-sponsored real-world administrative claims database, 2012 to 2018 title. Blood. 2019; 134.","DOI":"10.1182\/blood-2019-131264"},{"issue":"4","key":"344_CR18","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1080\/10428194.2017.1361035","volume":"59","author":"JP MacEwan","year":"2018","unstructured":"MacEwan JP, et al. Economic burden of multiple myeloma among patients in successive lines of therapy in the United States. Leuk Lymphoma. 2018;59(4):941\u20139. https:\/\/doi.org\/10.1080\/10428194.2017.1361035.","journal-title":"Leuk Lymphoma"},{"key":"344_CR19","doi-asserted-by":"publisher","unstructured":"Neves M, et al. Multiple myeloma in Portugal: burden of disease and cost of illness. Pharmacoeconomics, no. Mm, 2021. https:\/\/doi.org\/10.1007\/s40273-020-00993-5.","DOI":"10.1007\/s40273-020-00993-5"},{"key":"344_CR20","doi-asserted-by":"crossref","unstructured":"Lu\u00eds Antunes Francisco Rocha\u2010Gon\u00e7alves S\u00e9rgio Chacim Cinira Lef\u00e8vre Marta Pereira S\u00f3nia Pereira Aleksandra Zagorska Maria Jos\u00e9 Bento. Real\u2010world treatment patterns, resource use and cost burden of multiple myeloma in Portugal. Eur J Cancer Care. 2019;28(4).","DOI":"10.1111\/ecc.13026"},{"key":"344_CR21","doi-asserted-by":"publisher","unstructured":"Chae JW, Song CS, Kim H, Lee KB, Seo BS, il Kim D. Prediction of mortality in patients undergoing maintenance hemodialysis by Charlson Comorbidity Index using ICD-10 database. Nephron Clin Pract. 2011. https:\/\/doi.org\/10.1159\/000321525.","DOI":"10.1159\/000321525"},{"key":"344_CR22","doi-asserted-by":"publisher","unstructured":"Prenzler A, Zeidler J, Braun S, von der Schulenburg J-M. Bewertung von Ressourcen im Gesundheitswesen aus der Perspektive der deutschen Sozialversicherung. PharmacoEconomics German Research Articles 2010. 2013;8(1):47\u201366. https:\/\/doi.org\/10.1007\/BF03320765.","DOI":"10.1007\/BF03320765"},{"key":"344_CR23","unstructured":"Volkswirtschaftliche Kosten durch Arbeitsunf\u00e4higkeit 2019. 2019. https:\/\/www.baua.de\/DE\/Themen\/Arbeitswelt-und-Arbeitsschutz-im-Wandel\/Arbeitsweltberichterstattung\/Kosten-der-AU\/pdf\/Kosten-2019.pdf?__blob=publicationFile&v=3. Accessed 15 Apr 2021."},{"issue":"2","key":"344_CR24","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1093\/biomet\/87.2.329","volume":"87","author":"H Bang","year":"2000","unstructured":"Bang H, Tsiatis A. Estimating medical costs with censored data. Biometrika. 2000;87(2):329\u201343.","journal-title":"Biometrika"},{"issue":"29\u201330","key":"344_CR25","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1024\/1661-8157.96.29.1111","volume":"96","author":"U Kolyvanos Naumann","year":"2018","unstructured":"Kolyvanos Naumann U, K\u00e4ser L, Vetter W. Multiples myelom. Praxis. 2018;96(29\u201330):1111\u20139. https:\/\/doi.org\/10.1024\/1661-8157.96.29.1111.","journal-title":"Praxis"},{"key":"344_CR26","unstructured":"W\u00f6rmann B, et al. Leitlinie Multiples Myelom, Deutsche Gesellschaft f\u00fcr H\u00e4matologie und Medizinische Onkologie e.V. 2018."},{"key":"344_CR27","unstructured":"R. Koch-Institut. Krebs in Deutschland f\u00fcr 2017\/2018. 2017. [Online]. http:\/\/www.krebsdaten.de\/multiples-myelom. Accessed 21 Feb 2022."},{"issue":"7","key":"344_CR28","doi-asserted-by":"publisher","first-page":"A743","DOI":"10.1016\/j.jval.2016.09.2265","volume":"19","author":"R Vij","year":"2016","unstructured":"Vij R, et al. Healthcare resource utilization (HCRU) in relapsed\/refractory multiple myeloma (RRMM): comparison of EU and US cohorts in the preamble study. Value Health. 2016;19(7):A743. https:\/\/doi.org\/10.1016\/j.jval.2016.09.2265.","journal-title":"Value Health"},{"key":"344_CR29","doi-asserted-by":"crossref","unstructured":"Dimopoulos E, Meletios A. Kastritis. Managing myeloma with limited resources in the era of novel drugs. Leuk Lymphoma. 2018;59(10):2269\u20132270.","DOI":"10.1080\/10428194.2018.1476692"},{"key":"344_CR30","first-page":"59","volume":"4","author":"J Kenney","year":"2011","unstructured":"Kenney J. Advances in the management of multiple myeloma: implications for payers. Health Drug Benef. 2011;4:59\u201360.","journal-title":"Health Drug Benef"},{"issue":"6","key":"344_CR31","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1185\/03007995.2015.1031732","volume":"31","author":"SR Arikian","year":"2015","unstructured":"Arikian SR, et al. Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma. Curr Med Res Opin. 2015;31(6):1105\u201315. https:\/\/doi.org\/10.1185\/03007995.2015.1031732.","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"344_CR32","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s10198-020-01247-z","volume":"22","author":"F Hardtstock","year":"2021","unstructured":"Hardtstock F, et al. Healthcare resource utilization and associated cost of patients with bone metastases from solid tumors who are na\u00efve to bone-targeting agents: a comparative analysis of patients with and without skeletal-related events. Eur J Health Econ. 2021;22(2):243\u201354. https:\/\/doi.org\/10.1007\/s10198-020-01247-z.","journal-title":"Eur J Health Econ"},{"key":"344_CR33","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.2147\/DMSO.S214288","volume":"12","author":"T Wilke","year":"2019","unstructured":"Wilke T, et al. Real-world insulin therapy in German type 2 diabetes mellitus patients: patient characteristics, treatment patterns, and insulin dosage. Diabetes Metab Syndr Obes Targets Ther. 2019;12:1225. https:\/\/doi.org\/10.2147\/DMSO.S214288.","journal-title":"Diabetes Metab Syndr Obes Targets Ther"}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-022-00344-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-022-00344-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-022-00344-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T07:53:45Z","timestamp":1657785225000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-022-00344-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,24]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["344"],"URL":"https:\/\/doi.org\/10.1007\/s41669-022-00344-4","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,24]]},"assertion":[{"value":"16 May 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was supported by GlaxoSmithKline GmbH & Co. KG.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Franz Fischer and Robert Welte are employees of GlaxoSmithKline GmbH & Co. KG. Zeki Kocaata participated in this work as an employee of Ingress-Health and has no conflict of interest to declare. Thomas Wilke is the founder of IPAM e.V. and received honoraria from Boehringer Ingelheim Pharma, Bayer Health Care, GSK, Novartis, Sanofi-Aventis, Bristol Myers Squibb, Pfizer, and other pharmaceutical companies. Hermann Einsele, who is working as a physician in the field of oncology, supported the study as a scientific advisor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"As the study addressed a retrospective anonymized dataset, no ethical review was needed. However, the study protocol was reviewed by a scientific steering committee and the data owner (statutory health insurance, AOK PLUS). The work on the dataset conformed to all social security data protection requirements.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"As the study addressed a retrospective anonymized dataset, no informed consent of patients was needed.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The study was reviewed by a scientific steering committee and the data owner and approved for publication. All co-authors consented to publish the manuscript.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The dataset used to conduct the analysis is not publicly available. All data needed to evaluate the conclusions in the paper are present in the main text and\/or the Supplementary Materials.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"All data needed to evaluate the conclusions in the paper are present in the main text and\/or the Supplementary Materials. Statistical analyses were done using standard applications of the software packages mentioned in the method sections. Custom algorithms applied (i.e., identification of therapy lines) have been described in the main text and\/or the Supplementary Materials.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Conceptualization: Z.K., T.W., F.F., R.W.; Methodology: Z.K., T.W., F.F., E.H.; Formal analysis: Z.K.; Writing\u2013original draft preparation: T.W., Z.K.; Writing\u2013review and editing: Z.K., T.W., F.F., R.W.,E.H; Supervision: F.F., R.W.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}